Redeye gives a short comment on the exciting news that the FDA and IRLAB have an aligned view on a f...
Sales exceeded expectations at SEK40.4m, compared to our estimate of SEK35m.
Eevia Health Plc (publ) (”Eevia Health”, “Eevia” or “the Company”) concludes a transformative 2023, ...
Nettoomsättningen för det fjärde kvartalet uppgick till 9,7 MEURO (8,1), vilket motsvarade en ökning...
Högre motiverat värde Vi höjer vårt motiverade värde till 49-59 kr (43-53) per aktie på grund av ett...
Idag publicerade Fable Media (tidigare Future Gaming) sin delårsrapport för kv4 2023.
Redeye updates its view of Nanexa following the Q4 report and recent events in the company.
Redeye states the report aligned with our sales estimate, but periodization effects and organization...
Sales SEK 553m -8% vs. ABGSCe 599m Adj. EBIT ~SEK -5m vs.
Redeye provides its initial take on ADDvise’s Q4 2023 report, which came in moderately below our est...
Cereno Scientific is a clinical-stage biotech, developing treatments for cardiovascular diseases (CV...
SSH Communications Security Q4 report came in weaker than expected.
Redeye provides its initial comments on the Q4 2023 report from Fragbite.
Apart from the new label, Tarpeyo is supported by a higher price and 50-51% growth in prescribers an...
Artscape and Borosan temporary margin dampeners We forecast 10% EBITA growth in '24e Accumulated FCF...
Redeye comments on Thunderful Group’s Q4'23 report, which came in line with preliminary figures.
Delivering on FY guidance, Q4 EBITA +21% y-o-y and +15% vs cons North America & RoW better, Europe w...
We cut '23e-'25e adj. EBITDA by 15-2% Public sector weakness a drag on performance '24e EV/EBITA 4x ...
Apart from a write down of capitalized development related to the suspended projects NEX-18 and NEX-...
Redeye comments on Better Collective’s Q4-results which were in line with the preliminary outcome an...